CENTRAX

This brand name is authorized in Ireland

Active ingredients

The drug CENTRAX contains one active pharmaceutical ingredient (API):

1 Prazepam
UNII Q30VCC064M - PRAZEPAM

Prazepam is a benzodiazepine derivative and has depressant effects on the central nervous system. Benzodiazepines act at the level of the limbic, thalamic, and hypothalamic regions of the CNS and can produce any level of CNS depression required including sedation, hypnosis, skeletal muscle relaxation, and anticonvulsant activity.

Read about Prazepam

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
CENTRAX Tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
N05BA11 Prazepam N Nervous system → N05 Psycholeptics → N05B Anxiolytics → N05BA Benzodiazepine derivatives
Discover more medicines within N05BA11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: IE Health Products Regulatory Authority Identifier(s): 17124

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.